FibroBiologics files patent application for GLP-1 technology
FibroBiologics said it filed a U.S. patent application for a cell-based technology designed to continuously produce GLP-1 and other therapeutic peptides inside the body. The company said the approach is intended as an alternative to repeated injections or pills.